 Novocure Ltd NASDAQ: NVCR has announced final results from its phase 2 pilot HEPANOVA trial evaluating Tumor Treating Fields TTFields together with Bayer AGs OTC: BAYRY Nexavar sorafenib for hepatocellular cancer. The trial enrolled 27 patients, and 21 were considered evaluable. 